Search

Author/Creator Scheithauer, Werner

2. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer. Issue 8 (31st July 2014)

Authors:
Prager, Gerald W.; Braemswig, Kira H.; Martel, Alexandra; Unseld, Matthias; Heinze, Georg; Brodowicz, Thomas; Scheithauer, Werner; Kornek, Gabriela; Zielinski, Christoph C.
Journal:
Cancer science
Issue:
Volume 105:Issue 8(2014:Aug.)
Page Start:
996
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Issue 15 (November 2015)

Authors:
Tournigand, Christophe; Chibaudel, Benoist; Samson, Benoit; Scheithauer, Werner; Vernerey, Dewi; Mésange, Paul; Lledo, Gérard; Viret, Frédéric; Ramée, Jean-François; Tubiana-Mathieu, Nicole; Dauba, Jérôme; Dupuis, Olivier; Rinaldi, Yves; Mabro, May; Aucoin, Nathalie; Latreille, Jean; Bonnetain, F...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 15(2015)
Page Start:
1493
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Issue 23 (28th September 2015)

Authors:
Pavo, Noemi; Raderer, Markus; Hülsmann, Martin; Neuhold, Stephanie; Adlbrecht, Christopher; Strunk, Guido; Goliasch, Georg; Gisslinger, Heinz; Steger, Günther G; Hejna, Michael; Köstler, Wolfgang; Zöchbauer-Müller, Sabine; Marosi, Christine; Kornek, Gabriela; Auerbach, Leo; Schneider, Sven; Parsc...
Journal:
Heart
Issue:
Volume 101:Issue 23(2015)
Page Start:
1874
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Issue 3 (March 2018)

Authors:
ter Veer, Emil; van Rijssen, L Bengt; Besselink, Marc G; Mali, Rosa M A; Berlin, Jordan D; Boeck, Stefan; Bonnetain, Franck; Chau, Ian; Conroy, Thierry; Van Cutsem, Eric; Deplanque, Gael; Friess, Helmut; Glimelius, Bengt; Goldstein, David; Herrmann, Richard; Labianca, Roberto; Van Laethem, Jean-L...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 3(2018)
Page Start:
e151
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250–259]. (July 2022)

Authors:
Stahler, Arndt; Stintzing, Sebastian; von Einem, Jobst C.; Westphalen (Benedikt), Christoph B.; Heinrich, Kathrin; Krämer, Nicole; Michl, Marlies; Modest, Dominik P.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer...
Journal:
European journal of cancer
Issue:
Volume 169(2022)
Page Start:
223
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first‐line treatment within the randomized Phase III trial FIRE‐3 (AIO KRK‐0306). Issue 1 (6th September 2021)

Authors:
Liu, Lian; Erickson, Nicole Tonya; Ricard, Ingrid; von Weikersthal, Ludwig Fischer; Lerch, Markus M.; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Link, Hartmut; Höffkes, Heinz‐Gert; Moehler, Markus; Gesenhues, Alena B...
Journal:
International journal of cancer
Issue:
Volume 150:Issue 1(2022)
Page Start:
112
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer. (14th December 2020)

Authors:
Sobrero, Alberto; Lenz, Heinz‐Josef; Eng, Cathy; Scheithauer, Werner; Middleton, Gary; Chen, Wenfeng; Esser, Regina; Nippgen, Johannes; Burris, Howard
Journal:
Oncologist
Issue:
Volume 26:Number 2(2021)
Page Start:
e261
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Issue 10 (October 2016)

Authors:
Stintzing, Sebastian; Modest, Dominik P; Rossius, Lisa; Lerch, Markus M; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martin...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 10(2016:Oct.)
Page Start:
1426
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗